BioAge Labs, Inc (BIOA)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $239.87M
Last updated: Nov 17, 2026 at 4:15 PM ET
BioAge Labs, Inc (BIOA) Statistics
BioAge Labs (BIOA) has a market cap of $239.87M and an enterprise value of $187.20M. It kept -1253.60% of revenue as net income over the last 12 months. Its share count is up 28.07% from a year earlier.
Total Valuation
Enterprise value is 21.96% below the market cap, as cash exceeds debt.
| Market Cap | $239.87M |
|---|---|
| Enterprise Value | $187.20M |
| Latest price (Nov 17, 2026) | $5.10 |
Key Dates
The next earnings report is expected on Mar 22, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 22, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 27.2x and 0.7x.
| P/S Ratio | 27.2x |
|---|---|
| Forward P/S | 34.7x |
| P/B Ratio | 0.7x |
Price Statistics
The stock is down 34.62% over 52 weeks and trades 20.68% below its 50-day average.
| Beta (1Y) | 1.70 |
|---|---|
| 52-Week Change | -34.62% |
| 1-Month Change | +2.20% |
| 3-Month Change | -52.56% |
| 6-Month Change | -68.85% |
| Total Return (1Y) | -34.62% |
| Return vs SPY (1Y) | -49.74% |
| Max Drawdown (1Y) | -80.72% |
| Max Drawdown (3Y) | -88.23% |
| Sharpe Ratio (1Y) | -0.37 |
| Correlation with SPY (1Y) | 0.18 |
| 50-Day Average | $6.43 |
| 200-Day Average | $14.97 |
| 52-Week Range | $4.81 to $25.95 |
| RSI (14 Days) | 35.8 |
| Average Volume (20 Days) | 679.93K |
Financial Position
Current assets cover 15.51x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 15.51x |
|---|---|
| Quick Ratio | 15.51x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -31.12% and return on assets is -29.32% over the last 12 months.
| Return on Equity (ROE) | -31.12% |
|---|---|
| Return on Assets (ROA) | -29.32% |
| Asset Turnover | 0.03x |
| Receivables Turnover | 14.45x |
Scores
BIOA has an Altman Z-Score of 4.89, in the safe zone above 2.99, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 4.89 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 1 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $8.60M over the last 12 months is up 45.33% from the 12 months before.
| Revenue | $8.60M |
|---|---|
| Revenue Growth (YoY) | +45.33% |
| Gross Profit | $8.60M |
| Operating Income | -$120.54M |
| Pretax Income | -$107.27M |
| Net Income | -$107.80M |
| Reported EPS (TTM) | -$2.55 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 94.23% of the $367.65M in total assets.
| Cash and Equivalents | $52.67M |
|---|---|
| Total Debt | $0 |
| Net Cash | $52.67M |
| Net Cash Per Share | $1.15 |
| Working Capital | $276.03M |
| Shareholder Equity | $346.45M |
| Book Value Per Share | $7.55 |
| Total Assets | $367.65M |
| Total Liabilities | $21.20M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $484.00K of capital spending, operating cash flow left -$103.00M of free cash flow.
| Operating Cash Flow | -$102.52M |
|---|---|
| Capital Expenditures | $484.00K |
| Free Cash Flow | -$103.00M |
| FCF Per Share | -$2.24 |
| Depreciation and Amortization | $1.79M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -1401.81%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -1401.81% |
| Pretax Margin | -1247.46% |
| Net Margin | -1253.60% |
| FCF Margin | -1197.81% |
Dividends and Yields
BIOA does not pay a dividend. Its free cash flow yield is -43.99%.
| FCF Yield | -43.99% |
|---|---|
| Buyback Yield | -66.90% |
| Shareholder Yield | -66.90% |
Peer Position
Against 8 similar companies, BIOA has the highest P/S.
P/S RatioPeer median 1.0x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +12.08%
| P/S Ratio | 27.2x vs 1.0x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +45.33% vs +12.08% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About BIOA
What is BIOA's market cap?
BioAge Labs has a market cap of $239.87M. Its enterprise value, which adds debt and subtracts cash, is $187.20M.
How many shares of BIOA are outstanding?
BioAge Labs has 45.91M shares outstanding. The count is up 28.07% from a year earlier.
Does BIOA pay a dividend?
No. BioAge Labs does not pay a dividend.
How much debt does BIOA have?
BioAge Labs has $0 of total debt and $52.67M of cash and equivalents, a net cash position of $52.67M.
BIOA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors